2014 Alumni Professional Achievement Award Winner
For more than 33 years, John Hubbard has pioneered pharmaceutical research and development activity. Throughout his career, he has been directly responsible for drug discovery, clinical pharmacology, project management, commercial assessment of new chemical entities, global clinical operations, and pharmaceutical product development.
In the past, Hubbard has served as head of project management and new drug development for Hoechst-Roussel Pharmaceuticals (now Sanofi Pharmaceuticals) and was senior vice president and worldwide head of development operations for Pfizer Inc., responsible for global clinical trial management for more than 450 projects (Phase I-IV) per year. Since receiving his PhD in experimental psychology (cardiovascular psychophysiology) from UT in 1983, he has authored or coauthored three book chapters and 76 articles and abstracts in the areas of cardiovascular/autonomic pharmacology, clinical pharmacology, and drug development.
Prior to joining Pfizer, he was group president of Global Clinical Research Services at ICON Clinical Research PLC. Hubbard was responsible for ICON’s largest global business unit generating revenues of $725 million in 2009, when Fortune cited ICON as 49th on the list of the 100 Fastest Growing Companies.
From 2009 to 2018, Hubbard was adjunct professor of the premed and pharmaceutical product development program at West Chester University. After his tenure at Pfizer, he was chief executive officer at Bioclinica, a leading medical imaging and pharmaceutical development company, for three years before retiring from the position in 2018.
Now semiretired, Hubbard remains active in the industry through a variety of board and advisory roles. He serves as an independent director for Signant Health, Advarra, and Agile Therapeutics. He is also a healthcare strategic advisory board member at Genstar Capital, a San Francisco-based private equity firm specializing in software, healthcare, and industrial technology.
He received UT’s Accomplished Alumni Award in 2009, served as the 2012 College of Arts and Sciences commencement speaker, and received the 2013 Fred J. Epstein, MD Lifetime Achievement Award from the Children’s Brain Tumor Foundation.
He and his wife, Jeanne, are active in philanthropy, especially in the Philadelphia area, and are longtime, generous supporters of the UT Department of Psychology.
For more than 33 years, John Hubbard has pioneered pharmaceutical research and development activity. Throughout his career, he has been directly responsible for drug discovery, clinical pharmacology, project management, commercial assessment of new chemical entities, global clinical operations, and pharmaceutical product development.
In the past, Hubbard has served as head of project management and new drug development for Hoechst-Roussel Pharmaceuticals (now Sanofi Pharmaceuticals) and was senior vice president and worldwide head of development operations for Pfizer Inc., responsible for global clinical trial management for more than 450 projects (Phase I-IV) per year. Since receiving his PhD in experimental psychology (cardiovascular psychophysiology) from UT in 1983, he has authored or coauthored three book chapters and 76 articles and abstracts in the areas of cardiovascular/autonomic pharmacology, clinical pharmacology, and drug development.
Prior to joining Pfizer, he was group president of Global Clinical Research Services at ICON Clinical Research PLC. Hubbard was responsible for ICON’s largest global business unit generating revenues of $725 million in 2009, when Fortune cited ICON as 49th on the list of the 100 Fastest Growing Companies.
From 2009 to 2018, Hubbard was adjunct professor of the premed and pharmaceutical product development program at West Chester University. After his tenure at Pfizer, he was chief executive officer at Bioclinica, a leading medical imaging and pharmaceutical development company, for three years before retiring from the position in 2018.
Now semiretired, Hubbard remains active in the industry through a variety of board and advisory roles. He serves as an independent director for Signant Health, Advarra, and Agile Therapeutics. He is also a healthcare strategic advisory board member at Genstar Capital, a San Francisco-based private equity firm specializing in software, healthcare, and industrial technology.
He received UT’s Accomplished Alumni Award in 2009, served as the 2012 College of Arts and Sciences commencement speaker, and received the 2013 Fred J. Epstein, MD Lifetime Achievement Award from the Children’s Brain Tumor Foundation.
He and his wife, Jeanne, are active in philanthropy, especially in the Philadelphia area, and are longtime, generous supporters of the UT Department of Psychology.
